Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07186478 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis

Study acronym: I-FALMIN TB
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 22, 2025 (before its estimated October 20, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This study evaluates the potential of I-FALMIN, a supplement derived from toman fish (Channa micropeltes), as an additional source of albumin in patients with pulmonary tuberculosis. Tuberculosis patients often experience low albumin levels, which may slow down recovery. The purpose of this study is to determine whether giving I-FALMIN as a supplement, in addition to standard tuberculosis treatment, can improve albumin levels and support overall health status. The study will compare outcomes between patients who receive I-FALMIN and those who do not.
Trial Details
NCT Number NCT07186478
Lead Sponsor Hasanuddin University
Collaborators: RSUP Dr. Wahidin Sudirohusodo
Conditions
(from sponsor)		 Pulmonary Tuberculosis, Hypoalbuminemia
Related terms Hypoalbuminemia, Tuberculosis, Tuberculosis, Pulmonary
Enrollment 112 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov